Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1α and IL-1β[1].
| Animal Model: | Female C57/BL6 mice with IL-1α and IL-1β injection[1] |
| Dosage: | 0.0001-1 mg/kg |
| Administration: | Intraperitoneal injection, 0.0001-1 mg/kg, once |
| Result: | Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1α and IL-1β. |
